UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
________________________
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. |
On February 12, 2024, Xenetic Biosciences, Inc. (the “Company”), posted a Virtual Investor event video with the Company’s Chief Scientific Officer, Curis Lockshin, PhD., discussing preclinical data from the Company’s DNase I oncology platform.
A link to the video may be found at https://www.virtualinvestorco.com/wtm-xbio-8k and is incorporated herein by reference.
The video link is furnished pursuant to this Item 7.01 and shall not be deemed filed in this or any other filing of the Company with the Securities and Exchange Commission, unless expressly incorporated by specific reference in any such filing.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XENETIC BIOSCIENCES, INC. | |
| By: /s/ James Parslow | |
| Date: February 12, 2024 | Name: James Parslow |
| Title: Chief Financial Officer |
| 3 |
Cover |
Feb. 12, 2024 |
|---|---|
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Feb. 12, 2024 |
| Entity File Number | 001-37937 |
| Entity Registrant Name | Xenetic Biosciences, Inc. |
| Entity Central Index Key | 0001534525 |
| Entity Tax Identification Number | 45-2952962 |
| Entity Incorporation, State or Country Code | NV |
| Entity Address, Address Line One | 945 Concord Street |
| Entity Address, City or Town | Framingham |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 01701 |
| City Area Code | (781) |
| Local Phone Number | 778-7720 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |
| Common Stock, $0.001 par value per share | |
| Title of 12(b) Security | Common Stock, $0.001 par value per share |
| Trading Symbol | XBIO |
| Security Exchange Name | NASDAQ |
| Purchase Warrants | |
| Title of 12(b) Security | Purchase Warrants |
| Trading Symbol | XBIOW |
| Security Exchange Name | NASDAQ |